Advances in Cardiac SPECT and PET Imaging: Overcoming the Challenges to Reduce Radiation Exposure and Improve Accuracy

Canadian Journal of Cardiology

Volumn 29, Issue 3, 2013, Pages 275-284

  Small, Gary R ^a   Wells, R Glenn ^a   Schindler, Thomas ^b   Chow, Benjamin J W ^a   Ruddy, Terrence D ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 123; 15P(IODOPHENYL) METHYL PENADECANOIC ACID I123; FLUORODEOXYGLUCOSE F 18; TRACER; UNCLASSIFIED DRUG;

CARDIAC DYSSYNCHRONY; CARDIOVASCULAR MAGNETIC RESONANCE; DIAGNOSTIC ACCURACY; ECHOCARDIOGRAPHY; HEART ARRHYTHMIA; HUMAN; IMAGE QUALITY; ISCHEMIC HEART DISEASE; POSITRON EMISSION TOMOGRAPHY; RADIATION EXPOSURE; REVIEW; SARCOIDOSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

CORONARY ARTERY DISEASE; DIAGNOSIS, DIFFERENTIAL; EVIDENCE-BASED MEDICINE; HUMANS; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIATION DOSAGE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 84874296521     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cjca.2012.10.003     Document Type: Review

References (66)

1. Berman D.S., Shaw L.J., Min J.K., et al. SPECT/PET myocardial perfusion imaging versus coronary CT angiography in patients with known or suspected CAD. Q J Nucl Med Mol Imaging 2010, 54:177-200.
2. Fazel R., Dilsizian V., Einstein A.J., Ficaro E.P., Henzlova M., Shaw L.J. Strategies for defining an optimal risk-benefit ratio for stress myocardial perfusion SPECT. J Nucl Cardiol 2011, 18:385-392.
3. Henzlova M.J., Duvall W.L. The future of SPECT MPI: time and dose reduction. J Nucl Cardiol 2011, 18:580-587.
4. Small G.R., Chow B.J., Ruddy T.D. Low-dose cardiac imaging: reducing exposure but not accuracy. Expert Rev Cardiovasc Ther 2012, 10:89-104.
5. Henzlova M.J., Cerqueira M.D., Mahmarian J.J., Yao S.S. Stress protocols and tracers. J Nucl Cardiol 2006, 13:e80-e90.
6. Botvinick E.H. Current methods of pharmacologic stress testing and the potential advantages of new agents. J Nucl Med Technol 2009, 37:14-25.
7. Chow B.J., Beanlands R.S., Lee A., et al. Treadmill exercise produces larger perfusion defects than dipyridamole stress N-13 ammonia positron emission tomography. J Am Coll Cardiol 2006, 47:411-416.
8. Levine M.G., Ahlberg A.W., Mann A., et al. Comparison of exercise, dipyridamole, adenosine, and dobutamine stress with the use of Tc-99m tetrofosmin tomographic imaging. J Nucl Cardiol 1999, 6:389-396.
9. Verna E., Ceriani L., Provasoli S., Scotti S., Ghiringhelli S. Larger perfusion defects with exercise compared with dipyridamole SPECT (exercise-dipyridamole mismatch) may reflect differences in epicardial and microvascular coronary dysfunction: when the stressor matters. J Nucl Cardiol 2007, 14:818-826.
10. Schindler T.H., Schelbert H.H. " Mismatch" in regional myocardial perfusion defects during exercise and pharmacologic vasodilation: a noninvasive marker of epicardial vasomotor dysfunction?. J Nucl Cardiol 2007, 14:769-774.
11. Dilsizian V., Bacharach S.L., Beanlands R.S., et al. PET myocardial perfusion and metabolism clinical imaging. J Nucl Cardiol 2009, 16:651.
12. Marzullo P., Marcassa C., Sambuceti G., Parodi O., L'Abbate A. The clinical usefulness of electrocardiogram-gated Tc-99m methoxy-isobutyl-isonitrile images in the detection of basal wall motion abnormalities and reversibility of stress induced perfusion defects. Int J Card Imaging 1992, 8:131-141.
13. Marcassa C., Marzullo P., Parodi O., Sambuceti G., L'Abbate A. A new method for noninvasive quantitation of segmental myocardial wall thickening using technetium-99m 2-methoxy-isobutyl-isonitrile scintigraphy-results in normal subjects. J Nucl Med 1990, 31:173-177.
14. Smanio P.E., Watson D.D., Segalla D.L., Vinson E.L., Smith W.H., Beller G.A. Value of gating of technetium-99m sestamibi single-photon emission computed tomographic imaging. J Am Coll Cardiol 1997, 30:1687-1692.
15. Bateman T.M., Cullom S.J. Attenuation correction single-photon emission computed tomography myocardial perfusion imaging. Semin Nucl Med 2005, 35:37-51.
16. Utsunomiya D., Tomiguchi S., Shiraishi S., et al. Initial experience with X-ray CT based attenuation correction in myocardial perfusion SPECT imaging using a combined SPECT/CT system. Ann Nucl Med 2005, 19:485-489.
17. Einstein A.J., Johnson L.L., Bokhari S., et al. Agreement of visual estimation of coronary artery calcium from low-dose CT attenuation correction scans in hybrid PET/CT and SPECT/CT with standard Agatston score. J Am Coll Cardiol 2010, 56:1914-1921.
18. Mylonas I., Kazmi M., Fuller L., et al. Measuring coronary artery calcification using positron emission tomography-computed tomography attenuation correction images. Eur Heart J Cardiovasc Imaging 2012, 13:786-792.
19. Genest J., McPherson R., Frohlich J., et al. 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations. Can J Cardiol 2009, 25:567-579.
20. Seo Y., Mari C., Hasegawa B.H. Technological development and advances in single-photon emission computed tomography/computed tomography. Semin Nucl Med 2008, 38:177-198.
21. Hatton R.L., Hutton B.F., Angelides S., Choong K.K., Larcos G. Improved tolerance to missing data in myocardial perfusion SPET using OSEM reconstruction. Eur J Nucl Med Mol Imaging 2004, 31:857-861.
22. Garcia E.V. Physical attributes, limitations, and future potential for PET and SPECT. J Nucl Cardiol 2012, 19(suppl 1):S19-S29.
23. Travin M.I. Cardiac cameras. Semin Nucl Med 2011, 41:182-201.
24. Formiconi A.R. Collimators. Q J Nucl Med 2002, 46:8-15.
25. Darambara D.G., Todd-Pokropek A. Solid state detectors in nuclear medicine. Q J Nucl Med 2002, 46:3-7.
26. Gimelli A., Bottai M., Genovesi D., Giorgetti A., Di M.F., Marzullo P. High diagnostic accuracy of low-dose gated-SPECT with solid-state ultrafast detectors: preliminary clinical results. Eur J Nucl Med Mol Imaging 2012, 39:83-90.
27. Small G.R., Kazmi M., deKemp R.A., Chow B.J. Established and emerging dose reduction methods in cardiac computed tomography. J Nucl Cardiol 2011, 18:570-579.
28. Slomka P.J., Dey D., Duvall W.L., Henzlova M.J., Berman D.S., Germano G. Advances in nuclear cardiac instrumentation with a view towards reduced radiation exposure. Curr Cardiol Rep 2012, 14:208-216.
29. DePuey E.G., Bommireddipalli S., Clark J., Leykekhman A., Thompson L.B., Friedman M. A comparison of the image quality of full-time myocardial perfusion SPECT vs wide beam reconstruction half-time and half-dose SPECT. J Nucl Cardiol 2011, 18:273-280.
30. Schindler T.H., Magosaki N., Jeserich M., et al. Fusion imaging: combined visualization of 3D reconstructed coronary artery tree and 3D myocardial scintigraphic image in coronary artery disease. Int J Card Imaging 1999, 15:357-368.
31. Gemignani A.S., Muhlebach S.G., Abbott B.G., Roye G.D., Harrington D.T., Arrighi J.A. Stress-only or stress/rest myocardial perfusion imaging in patients undergoing evaluation for bariatric surgery. J Nucl Cardiol 2011, 18:886-892.
32. Bhavnani S.P., Heller G.V. Stress-only myocardial perfusion imaging. it is time for a change!. J Nucl Cardiol 2011, 18:836-839.
33. Bateman T.M., Heller G.V., McGhie A.I., et al. Multicenter investigation comparing a highly efficient half-time stress-only attenuation correction approach against standard rest-stress Tc-99m SPECT imaging. J Nucl Cardiol 2009, 16:726-735.
34. Ziadi M.C., Beanlands R.S. The clinical utility of assessing myocardial blood flow using positron emission tomography. J Nucl Cardiol 2010, 17:571-581.
35. Parkash R., deKemp R.A., Ruddy T.D., et al. Potential utility of rubidium 82 PET quantification in patients with 3-vessel coronary artery disease. J Nucl Cardiol 2004, 11:440-449.
36. Ziadi M.C., deKemp R.A., Williams K., et al. Does quantification of myocardial flow reserve using rubidium-82 positron emission tomography facilitate detection of multivessel coronary artery disease?. J Nucl Cardiol 2012, 19:670-680.
37. Ziadi M.C., deKemp R.A., Williams K.A., et al. Impaired myocardial flow reserve on rubidium-82 positron emission tomography imaging predicts adverse outcomes in patients assessed for myocardial ischemia. J Am Coll Cardiol 2011, 58:740-748.
38. Henneman M.M., Chen J., Ypenburg C., et al. Phase analysis of gated myocardial perfusion single-photon emission computed tomography compared with tissue Doppler imaging for the assessment of left ventricular dyssynchrony. J Am Coll Cardiol 2007, 49:1708-1714.
39. Aljaroudi W.A., Hage F.G., Hermann D., et al. Relation of left-ventricular dyssynchrony by phase analysis of gated SPECT images and cardiovascular events in patients with implantable cardiac defibrillators. J Nucl Cardiol 2010, 17:398-404.
40. Birnie D., de Kemp R.A., Tang A.S., et al. Reduced septal glucose metabolism predicts response to cardiac resynchronization therapy. J Nucl Cardiol 2012, 19:73-83.
41. Abraham A., Nichol G., Williams K.A., et al. 18F-FDG PET imaging of myocardial viability in an experienced center with access to 18F-FDG and integration with clinical management teams: the Ottawa-FIVE substudy of the PARR 2 trial. J Nucl Med 2010, 51:567-574.
42. Beanlands R.S., Chow B.J., Dick A., et al. CCS/CAR/CANM/CNCS/CanSCMR joint position statement on advanced noninvasive cardiac imaging using positron emission tomography, magnetic resonance imaging and multidetector computed tomographic angiography in the diagnosis and evaluation of ischemic heart disease-executive summary. Can J Cardiol 2007, 23:107-119.
43. D'Egidio G., Nichol G., Williams K.A., et al. Increasing benefit from revascularization is associated with increasing amounts of myocardial hibernation: a substudy of the PARR-2 trial. JACC Cardiovasc Imaging 2009, 2:1060-1068.
44. Holly T.A., Abbott B.G., Al-Mallah M., et al. Single photon-emission computed tomography. J Nucl Cardiol 2010, 17:941-973.
45. Chen J., Garcia E.V., Bax J.J., Iskandrian A.E., Borges-Neto S., Soman P. SPECT myocardial perfusion imaging for the assessment of left ventricular mechanical dyssynchrony. J Nucl Cardiol 2011, 18:685-694.
46. Epstein A.E., Dimarco J.P., Ellenbogen K.A., et al. ACC/AHA/HRS 2008 guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: executive summary. Heart Rhythm 2008, 5:934-955.
47. 123I-MIBG imaging: a meta-analysis from the studies performed in Japan. Ann Nucl Med 2011, 25:101-107.
48. Jacobson A.F., Senior R., Cerqueira M.D., et al. Myocardial iodine-123 meta-iodobenzylguanidine imaging and cardiac events in heart failure. Results of the prospective ADMIRE-HF (AdreView Myocardial Imaging for Risk Evaluation in Heart Failure) study. J Am Coll Cardiol 2010, 55:2212-2221.
49. Tamaki N., Yoshinaga K. Novel iodinated tracers, MIBG and BMIPP, for nuclear cardiology. J Nucl Cardiol 2011, 18:135-143.
50. Yamabe H., Fujiwara S., Rin K., et al. Resting 123I-BMIPP scintigraphy for detection of organic coronary stenosis and therapeutic outcome in patients with chest pain. Ann Nucl Med 2000, 14:187-192.
51. Berman D.S., Germano G., Slomka P.J. Improvement in PET myocardial perfusion image quality and quantification with flurpiridaz F 18. J Nucl Cardiol 2012, 19(suppl 1):S38-S45.
52. Friehling M., Soman P. Newer applications of nuclear cardiology in systolic heart failure: detecting coronary artery disease and guiding device therapy. Curr Heart Fail Rep 2011, 8:106-112.
53. Dilsizian V. Metabolic imaging for identifying antecedent myocardial ischemia and acute coronary syndrome in the emergency department. Curr Cardiol Rep 2011, 13:96-99.
54. Namdar M., Hany T.F., Koepfli P., et al. Integrated PET/CT for the assessment of coronary artery disease: a feasibility study. J Nucl Med 2005, 46:930-935.
55. Bonow R.O., Maurer G., Lee K.L., et al. Myocardial viability and survival in ischemic left ventricular dysfunction. N Engl J Med 2011, 364:1617-1625.
56. Small G.R., Beanlands R.S. Optimum assessment of myocardial viability. Brauwalds Heart Disease: A Textbook of Cardiovascular Medicine 2012, Elsevier, Philadelphia. 9th Ed. R.O. Bonow, D.L. Mann, D.P. Zipes (Eds.).
57. Youssef G., Leung E., Mylonas I., et al. The use of 18F-FDG PET in the diagnosis of cardiac sarcoidosis: a systematic review and metaanalysis including the Ontario experience. J Nucl Med 2012, 53:241-248.
58. Yu M., Nekolla S.G., Schwaiger M., Robinson S.P. The next generation of cardiac positron emission tomography imaging agents: discovery of flurpiridaz F-18 for detection of coronary disease. Semin Nucl Med 2011, 41:305-313.
59. Hachamovitch R., Rozanski A., Shaw L.J., et al. Impact of ischaemia and scar on the therapeutic benefit derived from myocardial revascularization vs. medical therapy among patients undergoing stress-rest myocardial perfusion scintigraphy. Eur Heart J 2011, 32:1012-1024.
60. Hachamovitch R., Hayes S.W., Friedman J.D., Cohen I., Berman D.S. Comparison of the short-term survival benefit associated with revascularization compared with medical therapy in patients with no prior coronary artery disease undergoing stress myocardial perfusion single photon emission computed tomography. Circulation 2003, 107:2900-2907.
61. Hachamovitch R., Rozanski A., Hayes S.W., et al. Predicting therapeutic benefit from myocardial revascularization procedures: are measurements of both resting left ventricular ejection fraction and stress-induced myocardial ischemia necessary?. J Nucl Cardiol 2006, 13:768-778.
62. Moroi M., Yamashina A., Tsukamoto K., Nishimura T. Coronary revascularization does not decrease cardiac events in patients with stable ischemic heart disease but might do in those who showed moderate to severe ischemia. Int J Cardiol 2012, 158:246-252.
63. Bui A.L., Horwich T.B., Fonarow G.C. Epidemiology and risk profile of heart failure. Nat Rev Cardiol 2011, 8:30-41.
64. Heller G.V., Calnon D., Dorbala S. Recent advances in cardiac PET and PET/CT myocardial perfusion imaging. J Nucl Cardiol 2009, 16:962-969.
65. Schinkel A.F., Bax J.J., Poldermans D., Elhendy A., Ferrari R., Rahimtoola S.H. Hibernating myocardium: diagnosis and patient outcomes. Curr Probl Cardiol 2007, 32:375-410.
66. Renaud J., Mylonas I., Yip K., et al. Low dose 3D PET rubidium ARMI (Alternative Radiopharmaceutical for Myocardial Imaging) multicentre trial standards and quality assurance. J Nucl Med 2012, 53(suppl 1):1805.